July 31, 2026

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL

Sub: Intimation for Press release of Financial Results for the quarter ended June 30, 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) we hereby submit the Press release of Financial Results for the quarter ended June 30, 2026.

You are requested to take the above information on your record.

Thanking You.

Yours Faithfully,
For ANLON HEALTHCARE LIMITED

Rasadia Punitkumar Rameshbhai

Digitally signed by Rasadia Punitkumar Rameshbhai
DN: c=IN, o=Personal, title=4798, pseudonym=13363440366292472861WAue1dglYIP1, 2.5.4.20=a003a5c41c134976122eef293c4077137aa4a1ecd74ed223ac0e8dcc8264a5a2, postalCode=360005, st=Gujarat, serialNumber=9067d666c809e74b4abe895e7d3c841cee4ae962d432d246758d2cb6b96167f3, cn=Rasadia Punitkumar Rameshbhai
Date: 2026.07.31 10:35:33 +05'30'

PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258

ANLON HEALTHCARE REPORTS 163% TOPLINE GROWTH, 150% EBITDA GROWTH AND 133% PAT GROWTH IN Q1FY27; STRENGTHENS ITS INTEGRATED PHARMACEUTICAL PLATFORM

Rajkot, 30th July 2026 – Anlon Healthcare Limited, one of India's leading manufacturers of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), announced its **unaudited Financial Results (Consolidated) for Q1FY27**.

Key Financial Highlights:

CONSOLIDATED FIGURES:

Particulars (₹ Cr)	Q1FY26	Q1FY27	Y-o-Y Change
Total Income	33.31	**87.62**	**163.02%**
EBITDA	6.26	**15.65**	**150.14%**
PAT	3.55	**8.28**	**133.13 %**

Key Developments During the Quarter

- **Strengthened integrated pharmaceutical platform** through the acquisition of **63.98% stake in Remember India Health Links Pvt. Ltd.** for a consideration of **₹5.38 Crore**, with the transaction completed on **8th May 2026**, making the company a subsidiary of Anlon Healthcare.
- **Expanded across the pharmaceutical value chain** with entry into the **Finished Dosage Formulations (FDF)** segment, complementing Anlon's existing API business and supporting its transition into an integrated pharmaceutical company.
- **Broadened product portfolio** through access to **30+ formulation dossiers**, strengthening capabilities in tablets, capsules and other pharmaceutical formulations.
- **Enhanced market presence** by expanding into **B2B APIs, domestic retail and hospital markets**, creating a broader pharmaceutical and healthcare platform.
- **Improved operational synergies** through integration of manufacturing and quality control processes, driving enhanced operational efficiencies and strengthening long-term scalability.

Management Commentary:

Mr. Punitkumar Rasadia – Chairman & Managing Director of Anlon Healthcare Limited, commented on the company's strong results,

"We have commenced FY27 on a strong note, delivering ***163.02% year-on-year growth in consolidated Total Income to ₹87.62 Crore, 150.14% growth in EBITDA to ₹15.65 Crore*** *and* ***133.13% growth in Profit After Tax to ₹8.28 Crore****. This performance reflects the strength of our diversified pharmaceutical portfolio, continued customer confidence and the positive contribution from our strategic acquisitions. Our healthy margins demonstrate the resilience of our business model and our focus on operational excellence.*

A key milestone during the quarter was the acquisition and integration of ***Remember India Health Links Pvt. Ltd.****, which marks our strategic entry into the* ***Finished Dosage Formulations (FDF)*** *segment. This acquisition provides access to* ***30+ formulation dossiers****, expands our presence across* ***B2B APIs, domestic retail and hospital markets****, and further strengthens our journey towards becoming an integrated pharmaceutical company. Together with Apiqo Organics and Bizotic Lifescience, these strategic investments significantly enhance our manufacturing capabilities, broaden our product portfolio and create meaningful operational synergies across the pharmaceutical value chain.*

Looking ahead, we remain focused on expanding our presence in regulated markets, scaling our CDMO business and leveraging our integrated pharmaceutical platform to drive sustainable growth. Backed by our enhanced manufacturing capabilities, diversified product portfolio and strategic acquisitions, we remain confident of achieving our long-term guidance of ***approximately 30% revenue CAGR over the next three years****, while* ***maintaining EBITDA margins in the range of 25%–30%****."*

About Anlon Healthcare Limited

Incorporated in 2013 and headquartered in Rajkot, Gujarat, Anlon Healthcare Limited is a research-driven pharmaceutical company engaged in manufacturing **high-purity pharmaceutical intermediates, APIs and expanding into Finished Dosage Formulations** through strategic acquisitions. The Company serves pharmaceutical, nutraceutical, personal care and animal health industries across **15+ countries** and continues to strengthen its integrated pharmaceutical platform through innovation, regulatory excellence and manufacturing expansion.

The company is among the few Indian manufacturers of **Loxoprofen Sodium Dihydrate**, **Ketoprofen**, and **Dexketoprofen Trometamol** which are the key APIs used for pain and inflammation management. Its products cater to multiple sectors, including **pharmaceuticals, nutraceuticals, personal care, and animal health**.

With **1,400-1,600 MTPA installed capacity**, **four R&D centers** and **a global presence across 15+ countries**, Anlon continues to advance health through innovation, quality, and sustainability.

Disclaimer

This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances.

For Further Information Please Contact

ConfideLeap Partners	**ConfideLeap Partners** info@confideleap.com +(91) 85911 45959 www.confideleap.com